


## PHARMACEUTICAL 2022

## Anixa Biosciences Inc Rank 81 of 466









## PHARMACEUTICAL 2022



## Anixa Biosciences Inc Rank 81 of 466



The relative strengths and weaknesses of Anixa Biosciences Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Anixa Biosciences Inc compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 70% points. The greatest weakness of Anixa Biosciences Inc is the variable Other Revenues, reducing the Economic Capital Ratio by 14% points.

The company's Economic Capital Ratio, given in the ranking table, is 247%, being 169% points above the market average of 78%.

Input Variable	Value in 1000 USD
Assets, Current	36,003
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	1,271
Liabilities, Non-Current	220
Other Assets	254
Other Compr. Net Income	0
Other Expenses	385
Other Liabilities	0
Other Net Income	7.8
Other Revenues	512
Property and Equipment	0
Research and Development	6,190
Selling, General and Administrative Expense	7,073

Output Variable	Value in 1000 USD
Assets	36,257
Liabilities	1,491
Expenses	13,648
Revenues	512
Stockholders Equity	34,767
Net Income	-13,128
Comprehensive Net Income	-13,128
Economic Capital Ratio	247%

